Zynex Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

LONE TREE, Colo., Nov. 6, 2017 /CNW/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that the November 2 presentation from Thomas Sandgaard, Founder and CEO, is now available for on-demand viewing at VirtualInvestorConferences.com.

LINK: https://tinyurl.com/1102postpr

Zynex's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

Recent Company Highlights

• 2^nd Q 2017 Results:
• Revenue grew 53% year over year
• Net income of $1.5 million increased 769% year over year
• Adjusted EBITDA of $2.0 million increased 7463% year over year
• Fourth consecutive quarter of net income, 80% gross margin and 38% operating margin
• Year to date cash flows from operations increased 146% to $1.9 million

About Zynex

Since 1996, Zynex Medical has been a leading provider of relief for patients with functional disability through the creation, distribution and marketing of the highest quality electrotherapy products available today. Zynex Medical continually strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing the highest technology and service standards in the electrotherapy industry.

Zynex, Inc., engineers, manufactures, markets and sells its own design of medical devices in three subsidiaries.
Zynex Medical™ is a provider of electrotherapy products for home use.
Zynex Monitoring Solutions™ develops products for cardiac monitoring for use in hospitals.
Zynex NeuroDiagnostics™ develops devices for EMG and EEG diagnostic purposes in the
neurology clinic markets

Zynex Medical's product line is fully developed, FDA-cleared, commercially sold, and has
been developed to uphold the Company's mission of improving the quality of life for patients
suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic
pain. Zynex Monitoring Solutions and Zynex NeuroDiagnostics are currently both in the
development stages without any significant revenues.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

SOURCE Zynex

Zynex, [phone]; Investor Relations Contact: Amato And Partners, LLC, Investor Relations Counsel, [email protected]; VirtualInvestorConferences.com, John Viglotti, VP, Investor Relations Products and Services, Cision / PR Newswire / MultiVu, 350 Hudson Street | 3rd Floor | New York, NY 10014, Phone [phone] | Mobile [phone],[email protected]